Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001293919 | SCV001482614 | uncertain significance | Rubinstein-Taybi syndrome due to CREBBP mutations | 2020-11-25 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Fulgent Genetics, |
RCV002486106 | SCV002778216 | uncertain significance | Rubinstein-Taybi syndrome due to CREBBP mutations; Menke-Hennekam syndrome 1 | 2022-03-05 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002538429 | SCV003492101 | benign | Rubinstein-Taybi syndrome | 2023-04-06 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003393959 | SCV004112476 | uncertain significance | CREBBP-related disorder | 2023-01-25 | criteria provided, single submitter | clinical testing | The CREBBP c.2854G>A variant is predicted to result in the amino acid substitution p.Val952Met. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.024% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-3820597-C-T). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004609724 | SCV005109038 | likely benign | Inborn genetic diseases | 2024-03-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |